|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Combining clinical factors and COX-2/C-MET/KRAS expression status, our models provided accurate prognostic information in CRC.
|
30720004 |
2020 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This study sought to evaluate short-term treatment with COX-2 inhibitors and acute changes in colonic PGE2 levels as predictors of long-term efficacy in a genetic model of colorectal cancer.
|
31797003 |
2020 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K/AKT pathway.
|
29339153 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population.
|
29552755 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
COX-2 expression was positive in 40/49 CRCs, bearing cytoplasmic and heterogeneous staining, from moderate to high intensity.
|
31614548 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The CRC protective effects of apiaceous vegetables are mainly due to the inhibitory effect of FaOH and FaDOH on NF-κB and its downstream inflammatory markers, especially COX-2.
|
31540047 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study was designed to assess the prophylactic potentials of probiotics (Lactobacillus acidophilus and Lactobacillus rhamnosus GG) in conjunction with celecoxib, a selective cox-2 inhibitor in 1,2 dimethylhydrazine dihydrochloride (DMH)-induced experimental colon carcinogenesis, a well-established, well appreciated and widely used model for colorectal cancer that shares many similarities to human sporadic colorectal cancer with respect to response to some promotional and preventive agents.
|
30183370 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In the COS-treated CRC group (CMCOS), COS protected mice from CRC by decreasing the disease activity index, tumor incidences and multiplicity, and the mRNA levels of COX-2, IL-6, TNF-α, IL-1β, IL-10, and IKK-β mRNA in colonic epithelial cells.
|
31620100 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The CRC condition was produced in response to COX-2 and IL-6 induced activation of JAK2/STAT3 which, in turn, was due to the enhanced phosphorylation of JAK2 and STAT3.
|
29580751 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
c-Myb and its Effector COX-2 as an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer.
|
31205515 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Increased synthesis of PGE<sub>2</sub> in CRC has been shown to occur through COX-2-dependent mechanisms; however, loss of the PGE<sub>2</sub>-catabolizing enzyme, 15-hydroxyprostaglandin dehydrogenase (15-PGDH, HPGD), in colonic tumors contributes to increased prostaglandin levels and poor patient survival.
|
30931980 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
COX-2 and proliferating cell nuclear antigen (PCNA) expression were assessed immunohistochemically. lncRNA-CCHE1 expression was upregulated in CRC tissues compared to adjacent non-cancerous tissues, and was significantly associated with larger tumor size, less differentiated histology, advanced dukes' stage, positive lymph node involvement and vascular invasion.
|
30484108 |
2019 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
A mechanistic analysis revealed that YAP1 promoted CRC-derived MDSC induction by suppressing PTEN expression to up-regulate COX-2, P-AKT and P-p65 in CRC-derived cells, leading to secretion of the cytokine granulocyte-macrophage colony-stimulating factor.
|
29770434 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
On the other hand, NPX and other NSAIDs are extensively studied in terms of colorectal cancer (CRC) prevention and inhibition, since it has been evidenced that COX-2 corresponds with the risk of the tumor occurrence and growth.
|
28260506 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study provided the evidence towards better antiproliferative effect of AR13 and AR15 in DMH-induced CRC through the blockade of COX-2/JAK-2/STAT-3 signal transduction pathway and could be demonstrated as useful anti-CRC candidate molecules for future anticancer therapy.
|
29229353 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
COX2 protein levels and nuclear COX2 expression were correlated with a poor prognosis of CRC patients.
|
29873317 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The Impact of Dietary Polyphenols on COX-2 Expression in Colorectal Cancer.
|
29068698 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE<sub>2</sub>.
|
30119635 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In the prostaglandin-dependent pathways, inhibition of cyclooxygenase (COX), particularly COX-2, is the primary mechanism known to be involved in aspirin-induced CRC suppression.
|
29552221 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
COX-2 mRNA levels increased similarly with statistical significance in IBD and CRC.
|
30186819 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting COX-2 and ALOX5.
|
28786533 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Patient databases also delineated the correlation of RIPK3 and COX-2 expression with colorectal cancer survival.
|
30012671 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results showed that cytoplasmic IDO1/COX2 coexpression could be used as an independent poor predictor for OS in CRC.
|
29853736 |
2018 |
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Colorectal cancer is characterized by aberrant Cyclooxigenase-2 (COX-2) and β-Catenin pathways.
|
28178650 |
2017 |
|
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer.
|
29037225 |
2017 |